Analyst Speak:
“The Cytomegalovirus Diagnostics Market is anticipated to reach about US$ 1,763.2 Mn by 2025, and the market is anticipated to expand at a significant CAGR over seven years of forecast period 2019-2025 due to increase in the prevalence of cytomegalovirus infection around the world”.
Precision Business Insights (PBI) in its report titled “Cytomegalovirus Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over six years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The cytomegalovirus diagnostics market size was accounted for US$ XX in 2018 and anticipated to account for US$ 1,763.2 Mn by 2025. Increased incidence of CMV and congenital CMV is a major factor creates demand for cytomegalovirus diagnostics market in the forthcoming period. According to Center for Disease Control and Prevention 1 per 150 infants are born with CMV infection in U.S. Moreover, rise in R&D for the development of innovative diagnostic tests, increase in health awareness among the population, and fundraising from public and private sectors for the R&D activities are anticipated to propel the CMV diagnostics market. However, lack of awareness about CMV infection in underdeveloped countries, high cost of diagnosis, and lack of favorable reimbursement policies are anticipated to hamper the growth of cytomegalovirus diagnostics market over the forecast timeframe.
Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=16046
Cytomegalovirus diagnostics market segmented on the basis of test type, application, end user, and regions.
Molecular Diagnostics Segment Expected to Dominate the Market
Based on test type, the cytomegalovirus diagnostics market is segmented into serology, cell culture, antigenemia assay, polymerase chain reaction amplification, immunohistochemistry, nucleic acid sequence based amplification, molecular diagnostics, and hybrid capture assay. Molecular diagnostic tests remain the largest share in cytomegalovirus diagnostics market owing to high accuracy with the test results and launch of newer diagnostic tests into market. For instance, in December 2014, Roche Diagnostics launched Cobas CMV assay for use on the Cobas 6800/8800 Systems that offers the exceptional performance that clinicians need when treating cytomegalovirus infection in transplant recipients receiving anti-viral therapy. In addition, serology tests growing at prominent growth rate owing to low cost of tests and launch of advanced test kits into market.
North America Dominated the Cytomegalovirus Diagnostics Market
Precision Business Insights (PBI), cytomegalovirus diagnostics market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America accounted for major revenue share in CMV diagnostics market owing to surge in the prevalence of CMV infection in U.S and Canada. Moreover, rise in adoption of technologically advanced diagnostic tests, favorable reimbursement policies, and frequent test approval by FDA for the detection of CMV infection. Asia Pacific CMV diagnostics market creates lucrative opportunities over the forecast years owing to surge in aging population and rise in medical tourism in the region.
Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players enhance the revenue of cytomegalovirus diagnostics market
In December 2018, Meridian Biosciences, Inc. received FDA approval for Alethia CMV Molecular Amplification Test designed to detect congenital Cytomegalovirus (cCMV) infection in newborns from saliva sample
For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-cytomegalovirus-diagnostics-market/

Key player’s profiles in the report are Becton, Dickinson and Company, Affymetrix, Inc., Bio-Rad Laboratories, Inc., Meridian Biosciences, Inc., F. Hoffmann-La Roche Ltd., Olympus Corporation, Johnson & Johnson, Siemens Healthcare, Abbott Laboratories, Inc., and Thermo Fisher Scientific, Inc.
Detailed Segmentation
By Test Type
o Serology
o Cell culture
o Antigenemia assay
o Polymerase Chain Reaction Amplification
o Immunohistochemistry
o Molecular Diagnostics
o Nucleic acid sequence-based amplification (NASBA)
o Hybrid capture assay
By Application
o Retinitis
o Pneumonia
o Gastrointestinal Ulcers
o Encephalitis
o Others (Mouth Ulcers, Pharyngitis, etc.)
By End-User Type
o Hospitals
o Diagnostic Centers
o Others
Geography
o North America
• US
• Canada
o Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
o Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights